<u>දූරකථන</u>	) 011 2669192 , 011 2675011		මගේ අංකය	)
தொலைபேசி	) 011 2698507, 011 2694033	as The State of th	எனது இல	)
Telephone	) 011 2675449 , 011 2675280		My No.	)
<b>ෆැක්ස්</b>	) 011 2693866			
பெக்ஸ்	) 011 2693869		ඔබේ අංකය	)
Fax	) 011 2692913		உமது இல	EPI/151/1/2017
			Your No. :	)
විද්යුත් තැපෑ,	) postmaster@health.gov.lk			
மின்னஞ்சல் முகவரி	)	සුවසිරිපාය	0	117
e-mail	)		දිනය	117
08 08		சுவசிரிபாய	திகதி	) <del>13/</del> 02/2017
වෙබ් අඩවිය	) www.health.gov.lk	CHINAL CIDID AND	Date	)
இணையத்தளம்	)	SUWASIRIPAYA		
website	)			

සෞඛ්ය පෝෂණ සහ දේශීය වෛදය අමාතසාංශය சுகாதார, போசணை மற்றும் சுதேச வைத்திய அமைச்சு Ministry of Health, Nutrition & Indigenous Medicine

Provincial Directors of Health Services,

Regional Directors of Health Services,

Heads/ Directors of Institutions,

Directors of National Hospital/Teaching Hospitals/Provincial & District General Hospitals, Base Hospitals,

All Medical Superintendents of other Hospitals,

Heads of Decentralized units,

Provincial CCP,

All Regional Epidemiologists/ Medical Officers (Maternal and Child Health),

All Medical Officers of Health,

Measles, Rubella, Congenital Rubella Syndrome (CRS) elimination initiative - Sri Lanka
Measles is a highly infectious viral disease responsible for a high degree of morbidity and
mortality among children including complications of pneumonia (1-6%), diarrhoea (8%), Otitits
Media (7-9%), subacute sclerosing panencephalitis (SSPE) (1 per 100,000 cases), Keratitis and
Corneal scaring are common with Vitamine A deficiency.

Fatal cases of measles are now rarely reported in Sri Lanka after successful implementation of the National Immunization Programme, including 2 doses of measles, mumps and rubella (MMR) vaccination at 9 months and 3 years of age.

The measles vaccine was first introduced into the National Immunization Programme in Sri Lanka in 1984. Since then, morbidity and mortality of measles were reduced remarkably but outbreaks have been experienced in 1999-2000 and 2013-2015. Considering the requirement to enhance the population level immunity, 2<sup>nd</sup> dose of measles containing vaccine has been introduced with the measles, rubella (MR) vaccine in 2001. In 2011, MMR vaccine was introduced in 2 doses at the age of 1 year and at the age of 3 years, replacing measles (9 months) and MR (3 years) vaccines. But, considering the morbidity patterns and sero survey evidence during the measles outbreak situation in 2013-2015, the Advisory Committee on Communicable Diseases (ACCD) has decided to re-schedule the MMR 1<sup>st</sup> dose at 9 months of age, continuing the 2<sup>nd</sup> dose at 3 years.

Rubella is a mild disease affecting children and adults. However rubella in pregnant women is important as the virus is transmitted to the foetus across the placental barrier, sometimes with significant teratogenic effects. Rubella vaccine was introduced into the National Immunization Programme in 1996, targeting all reproductive age females of 11- 44 years, with the objective of preventing congenital rubella syndrome (CRS). This was carried out as a school based programme by giving rubella vaccine to all children aged 11-15 years, and vaccinating the rest at the community clinics. Number of measles and CRS cases have markedly reduced and surveillance of measles, rubella and CRS was strengthened in 2005-2010 under the plan of 'intensification of the surveillance and Laboratory confirmation was made available for all suspected cases of Measles, Rubella and CRS from there to date.

# Acceleration of measles, rubella, CRS Elimination Plan 2017-2020

In par with the Regional Measles, Rubella and CRS elimination strategic plans, Sri Lanka has set the goal of elimination of Measles, Rubella, CRS by 2020.

Vision: Sri Lanka is free from measles, rubella and CRS

Goal: To achieve and sustain measles, rubella and CRS free status in Sri Lanka

<u>Objectives</u>: To achieve and maintain zero endogenous transmission of measles, rubella and CRS in Sri Lanka and identify and contain possible imported outbreaks

#### **Elimination targets:**

- Zero endogenous measles cases by 2020
- Zero endogenous rubella cases by 2020
- Zero CRS case/ 100,000 live births by 2018

# Components of elimination strategies:

- Achieve and maintain high levels of population immunity by providing two doses of measles and rubella containing vaccines with high vaccination coverage
- Strengthened disease surveillance including laboratory confirmation of all suspected cases of measles, rubella, CRS cases: case based investigation
- Strengthen country preparedness for outbreak prevention and response : contain outbreaks early
- Adequate patient care management to prevent the transmission and mortality
- Perform research to generate evidence for cost effective implementation strategies for measles, rubella, CRS elimination

# Measles and Rubella vaccination

 All eligible children who have completed the age of 9 months and the age of 3 years are to be vaccinated with MMR vaccine according to the current National Immunization schedule in Sri Lanka

- Required to achieve and maintain above 95% coverage in each of the two doses of MMR vaccine at the national, district and Medical Officer of Health (MOH) and Public Health Midwife (PHM) area levels
- If any child is found unvaccinated / missed for measles or rubella at any age, vaccinate with two doses of MMR with minimum of 6-8 weeks interval
- Ensure all women in the reproductive age are protected with at least one rubella containing vaccine (RCV)
- Ensure that that all women are protected/vaccinated for rubella at the time the Public Health Midwife (PHM) includes them in the Eligible Couple Register or at the earliest contact
- If any pregnant woman is found unvaccinated or with doubtful vaccination against rubella (and if the family has not been completed) she should be vaccinated with RVC after delivery, to prevent a future CRS case
- Once MMR (10 dose) vial is planned to open in the scheduled immunization clinic session and if the number of children planned for the days is less than the number in the opened vials for the day, plan and take necessary measures to vaccinate adults (up to 45 year) who are without proper history of measles and rubella vaccination using the remaining MMR doses for the day without discarding (after screen for contraindications and AEFI)

#### **Surveillance Case definitions**

Surveillance case definition of measles and rubella

Any person with "Fever and Maculopapular (i.e. non vescicular) rash" should be notified as either suspected measles or rubella case based on the clinical judgment of the treating clinicians / health care personnel

#### Surveillance case definition of CRS

Any infant with: maternal history of Rubella infection and / or with signs and symptoms from following categories

- cataract, congenital glaucoma, pigmentary retinopathy, congenital heart disease (PDA/peripheral pulmonary artery stenosis/VSD), Loss of hearing
- Purpura, splenomegaly, microcephaly, mental retardation, meningo-encephalitis, radiolucent bone disease, jaundice (within 24 hours of delivery)

or

 Laboratory data consistent with Congenital Rubella Infection (Rubella IgM positive or Rubella virus isolated)

# Measles, Rubella, CRS case reporting

All suspected "measles and rubella" patients with "fever and maculopapular rash" should be notified by all medical officers who are treating the patient at first contact of the patient.

All other health care staff including field health staff, who meet with a patient of "fever and maculopapular rash" are required to inform to the immediate contact health authority for proper notification.

All hospitals where specialist paediatricians and / or physicians are available, are sentinel site hospitals for active surveillance for Measles/Rubella/CRS and weekly zero reporting.

- All suspected Measles and Rubella patients should be notified to the Epidemiology Unit through the updated 'Suspected Measles / Rubella Patient Information Form' (EPID/151/2/2015, Blue Form) [Annexure 1] filled by the Clinician/Medical Officer who is treating the patient at first patient contact.
- The routine notification should to be sent to the Medical Officer of Health (MOH) of the patient's residential area (Notification of Communicable Diseases: Health-544, Annexure 2) for all suspected cases of Measles, Rubella, CRS
- All <u>suspected CRS cases</u> need to be reported to the Epidemiology Unit immediately by phone/fax/e-mail and <u>special investigation form (EPID/DS/CRS/2013)</u> [Annexure 3] is required to be properly completed by the clinician/medical officer who is treating the patient at the health institution and to be sent to the Epidemiology Unit.
- All infection control nursing officers (ICNO) at the sentinel site hospitals are expected to
  maintain Measles/Rubella and CRS registers (Format: Annexure 4 and 5). The infection
  control nurses are also expected to visit medical, paediatric, obstetric, cardiology,
  ophthalmology and ENT wards regularly for detection of cases (all Measles, Rubella,
  CRS), actively look for cases and notify promptly to the Epidemiology Unit.
- All suspected cases of Measles, Rubella/CRS presented to sentinel site hospitals should be included in the Weekly reporting form for AFP, Measles, Rubella cases from hospital (sentinel sites) EPID/37/5/R2004 (Annexure 6) [or in the web based system which will be trained during the year], and should be completed for the week ending date of Friday and should be sent to the Chief Epidemiologist, Epidemiology Unit, Colombo with copy to the Regional Epidemiologist. This form should be sent even if no cases have been detected ("Nil" reporting) for the week. A total of 52 reports should be received from each site per year and the timeliness of the return needs to be maintained at 7 days to be received at the Epidemiology Unit. The performance rate of completeness and the timeliness of the return will be measured to maintain the surveillance performance.
- The patients identified in other health institutions including General Practitioners and private health care institutions, are required to be promptly notified to the relevant MOH (Notification of Communicable Disease, [Health 544] form or any other means of notification) and the laboratory confirmation should be carried out as instructed.
- The Medical Officer of Health of the Patients residence (in an institutional outbreak, the MOH of the institution belonged) has to proceed with the routine surveillance procedure, contact tracing and outbreak prevention for all notified or community detected Measles, Rubella, CRS cases and complete the special field investigation form for all clinically confirmed measles or rubella cases (irrespective of the laboratory confirmation or the availability of results.

Clinically confirmed measles case	Clinically confirmed rubella case
Fever and maculopapular rash patient with at least one of the following:  Cough Coryza (i.e. runny nose) Conjunctivitis (i.e. red eyes)	Fever with maculopapular rash and arthralgia, arthritis, lymphadenopathy (usually suboccipital/ postauricular/ cervical) or conjunctivitis

- All clinically confirmed cases of Measles, Rubella and suspected CRS need to be completed with updated special investigation forms by the MOH ([EPID/DS/MEASLES/2007], [EPID/DS/RUBELLA.2007], [EPID/DS/CRS/2013] ) (Annexure 7, 8 & 3) and duly completed forms should be sent to the Epidemiology unit as early as possible, maximum with 2 weeks delay from the date of the notification.
- If the notified/clinically confirmed measles/rubella case has not been tested for laboratory confirmation due to any reason by the health institution, the MOH should perform the laboratory testing at the time of special field investigation as per instructions in the Epidemiology Unit letter No: EPID/151/2011 dated 20/09/2012.
- All Measles/Rubella cases detected at the community level by any of the public health staff, need to be adequately investigated, in accordance with the routine surveillance and special investigation procedure, with laboratory testing procedure to complete case based investigation by the MOH.

#### Laboratory investigations for suspected Measles/Rubella and CRS cases

• Two types of samples should be collected from all suspected measles and rubella cases

Sample for Virus isolation	Sample for detection of IgM (recent infection)
Nasal and throat swabs (in virus transport medium) preferably in the first 5 days of the onset of rash	2-3 ml blood sample preferably from 3 <sup>rd</sup> to 28 <sup>th</sup> day of the onset of rash

- A blood sample of 2-3ml for Measles /Rubella IgM should be collected from each suspected case of Measles, or Rubella from the 3<sup>rd</sup> day to 28<sup>th</sup> day of the onset of signs and symptoms, into a sterile, dry, screw capped container without any anti coagulant.
- A blood sample for Rubella IgM or for TORCH screen (as for Toxoplasma, Rubella, Cytomegalovirus, Herpes simplex virus in screening for congenital abnormalities) should be taken from all suspected infants of CRS and from newborns in instances where the mother has declared a history of suspected/confirmed Rubella infection in any gestational age of pregnancy.
- If any pregnant woman who does not give a history of Rubella vaccination is identified in any Obstetric Unit, she is required to be tested for Rubella IgM (before or after delivery) to identify possible recent Rubella infection during gestational period. In case a positive result is obtained, the baby is required to be investigated on delivery and followed up for possible CRS.

- Once the blood sample has been collected, it should be labeled and left at room temperature for about 30 minutes for clot formation. The sample should be sent as early as possible to the Measles and Rubella, National Reference Laboratory, Medical Research Institute (MRI), Colombo with a properly completed specimen request form (Annexure 9: "Specimen Request Form: Measles and Rubella, National Reference Laboratory, Medical Research Institute (MRI), Colombo). The sample should be transported in a cold box with ice cubes / ice packs to maintain cold temperature.
- If a facility to centrifuge is available, properly labelled separated serum should be sent to the MRI for Measles or Rubella IgM detection.
- The serum / clotted blood sample should be received at the laboratory within 48 hours of
  collection and if there is any delay of transport more than 6 hours the sample should be
  refrigerated until dispatch to prevent destruction of antibodies.
- Naso-pharyngeal aspirate, throat swab or gingival swab is collected within the first 5 days
  of the onset of symptoms for measles / rubella virus detection. Samples should be
  collected in to the container with virus transport medium (VTM) and labelled. Samples
  should be stored immediately at the refrigerator and transport in ice to maintain cold
  temperature with the completed specimen request form (annexure 9). Specimen
  collection containers (VTM + swabs) are provided. Contact infection control nursing
  officer (ICNO) of the hospital or Regional Epidemiologist of the district.

# Measles, rubella outbreak response:

- Routine surveillance for outbreak detection and prevention after notification (initial Public health Inspector visit, field level investigation with Health H- 411 / H-411a, and MOH case based special form investigation including laboratory confirmation should be completed within 14 days of the onset of the rash)
- Even a single laboratory confirmed measles, or rubella case is detected, it should be considered as an outbreak and following measures should be taken
  - Immediate notification to the Epidemiology Unit/ National focal point for Measles Rubella Elimination Programme(Epidemiology Unit )/RDHS/ Provincial CCP/ Regional Epidemiologist
  - If any unvaccinated/ unprotected child (2 doses of MMR or adult (up to 45 years) in the household, take measures to provide MMR vaccination at earliest possible, preferably within 14-21 days of the onset of the index laboratory confirmed case
  - Screen 30-50 households or households of 1 km radius around the index household, to identify any unvaccinated children below 15 years: take measures to vaccinate if any
  - Exclusion of the continuation of the outbreak:
    - Follow up contacts for 2 incubation period cycles (minimum of 28 days)
    - identify all "fever and maculopapular rash" cases from the area and send samples for laboratory testing (include into the surveillance system)
  - Inform to Epidemiology Unit the action taken

#### Additional information

- Unprotected travellers to measles or rubella (with unknown history or unvaccinated for measles and not contracted measles or rubella disease),
  - travelling to an endemic country for any of these diseases, are advised to vaccinate/receive at least one MMR dose, with a minimum of 1 month before the travel date, from the nearest MOH office
  - any unprotected traveller, returning from an endemic country, develops fever and rash within 14 to 21 days of the return should be considered as a possible imported case of measles or rubella and should be adequately investigated, to prevent community transmission
- Measles, Rubella vaccination and surveillance activities in disaster situations should be paid special attention, and should continue with routine immunization. Contact Measles, Rubella, CRS elimination programme at the Epidemiology Unit, Consultant CCP, Regional Epidemiologist, or the area MOH to assess the situation, and advise and actions for special vaccination campaigns and prevention of possible outbreaks
- Measles / Rubella outbreak prevention and response, specimen collection guidelines (including field level)[ as per Epidemiology Unit letter No: EPID/151/2011 dated 20/09/2012], standard operation procedure (SOP) for specimen collection and transport, Accelerated measles, rubella, CRS elimination plan 2017-2020 are available in the website: <a href="http://www.epid.gov.lk">http://www.epid.gov.lk</a>, under disease information, Measles, Rubella, CRS elimination programme
- Additional information contact: Measles, Rubella, CRS Elimination Programme, Epidemiology Unit, No: 231, De Saram Place, Colombo 10, <a href="mailto:chepid@sltnet.lk">chepid@sltnet.lk</a>, Tel:0112695112, fax: 0112696583

Please bring the contents of this circular to the notice of all relevant staff at your institution/district/province and arrange to implement the programme accordingly.

Dr. J.M.W. Jayasundara Bandara Director General of Health Services Ministry of Health Dr. J. M. W. Jayasundara Bandara
Director General of Health Services (Acting)
Ministry of Health, Nutrition & Indigenous Medicine,
No. 385, "Suwasiripaya",
Rev. Baddegama Wimalawansa Thero Mw,
Colombo 10.

# Copy:

- Secretary Health
- DDG/PHS 1
- DDG/PHS 11
- DDG/MS I and II
- DDG/Laboratory Services
- Chief Epidemiologist
- Director/ Private Healthcare Institutions
- Director/ MCH
- Director/FHB
- Director/NIHS
- Directors / Millitary hospitals

# EPIDEMIOLOGY-UNIT - MINISTRY OF HEALTH Measles / Rubella Elimination Initiative Suspected Measles / Rubella Patient Information

Please Mark	For Office use only
Measles Rubella	Mea/Rub ID Code SRL/

Inward patient	Ward No.	BHT No.	Date of Admission	OPD	oatient ,	OPD No
res No				Yes	No	
articulars of the I	Patient					
Name				*************		
Address				• • • • • • • • • • • • • • • • • • • •		
		) Jermeryn			······································	
Telephone			***************************************			
MOH Area				***********	,	
District Date of Bir						• • • • • • • • • • • • • • • • • • • •
Age	in :-			Date		
Sex		Male 🗌	Female 🗋			
nical History						
Date of ons	in consider it	Year [		Date		
Date of ons	et of rash :-	Year [_][	□□ Month □□	Date		
Cough						
Coryza						
Conjunctivit	is 🗍					
Lymphadend	pathy 🔲	(sub occipital /	post auricular / cervic	al)		
Other (specif	ξ <b>)</b>	to management				
		Serology [	Virus Isolation			
cimen collection						
imen details		spatch to	Date of collection of s		Date of MRI	dispatch to
cimen collection cimen details e of collection of b	lood Date of d		(Nasal/Throat swabs	ioi	''''	
cimen details of collection of b			(Nasal/Throat swabs Virus Isolation)			•
imen details of collection of b						

Date Signature ;

සෞඛාය / **සහානු**ගාර / Health - **544** 

# බෝවෙන රෝග පිළිබඳ නිවේදනය தொற்றுநோய் பற்றிய அறிவிப்பு NOTIFICATION OF A COMMUNICABLE DISEASE

ආයතනය / நிலையம் / Institute		රෝගය / ශු	நாய் / Disease	
රෝගියාගේ නම* நோயாளியின் பெயர் Name of Patient		සෑදුණු දිනය ஆரம்பித்த Date of Ons	திகதி 💄	
*ළමා රෝගීන්ගේ මව/පියා/භාරකරුගේ නම நோயாளி சிறுவராயின் பெற்றோர்/பாதுகாவல Peaditric patients- Name of Mother/Father	லர் பெயர்	ඇතුලත් කළ அனுமதித்த Date of adn	திகதி >	
ඇඳ ඉහපත් අංකය සட්ශුඛ නිட්කෙட මුඛ. B.H.T. No.	වාට්ටුව ඛාලුණ Ward	වයස வயது Age	ස්තුී/පුරුෂ භා ⊔πබ Sex	ల్ మార్క్ కార్డ్
රසායනාගාර වාර්තා (තිබේනම් පමණක්) முக்கிய ஆய்வு முடிவுகள் (பெறக்கூடியதாக Laboratory Results (If available)	இருப்பின்)			
රෝගියාගේ නිවසේ ලිපිනය (මහජන සෞඛා நோயாளியின் வீட்டு விலாசம் (நோயாளியின Home address of Patient (To trace the patie	ர் வீட்டை அடையாளம் கா	ண்பதற்கு வசதியாக)		
				•••••
රෝගියාගේ තිවසේ දුරකථන අංකය நோயாளியின் வீட்டு தொலைபேசி இல Patient's Home Telephone No.				
දනුම් දෙන්නාගේ අක්සන නම அறிவிப்பவரின் கையொப்பம் பெயர் Signature of Notifier Name			තිරම தஸ்து tus	 දිනය නිසනි Date

කරුණාකර බෝවෙන රෝග පිළිබඳ ලැයිස්තුව සඳහා පසුපිට බලන්න மறுபக்கத்திலுள்ள அறிவிக்கப்படவேண்டிய நோய்களின் பட்டியலைப் பார்க்கவும் Please see overleaf for the list of Notifiable Diseases.

# දනුම් දිය යුතු බෝවන රෝග ලැයිස්තුව அறிவிக்கப்பட வேண்டிய நோய்களின் படடியல்

### List of Notifiable Diseases

(Approved by the Advisory Committee on Communicable Diseases on 11th February 2005)

අ" කාණ		பிரிவு A		Group-A	
0	කොළරාව		வாந்திபேதி	. 0	Cholera
	මතාමාරිය	0	பிளேக் (கொள்ளை நோய்)	0	Plague
	කාහ උණා		மஞ்சள் காய்ச்சல்	9	Yellow Fever
ආා" කා∢	න්ඩය	பிரிவு B		Group-B	
0	උගු බාලක පක්ෂගාත රෝගය		இளம்பிள்ளை வாதம் / சடுதியான		Acute Poliomyclitis / Acute Flace
0	පැපොල රෝගය		தளர்ச்சி வாதம்		Paralysis
	ඩෙංගු උණ / ඩෙංගු රක්තපාත උණ		கொப்பளிப்பான்	ə	Chicken pox
9	ගලපටලය		டெங்கு காய்ச்சல் / டெங்கு குருதிப்பெருக்கு காய்ச்சல்		Dengue Fever / Dengue
	රක්ත අතීසාරය		தொண்டைக் கரப்பன்		Haemorhagic Fever
0	නිදිකර්පථපුදාහය		வயிற்றோட்டம்	9	Diptheria
9	අාත්තුික උණ		மூளைக்காய்ச்சல் (என்கெபலைடிஸ்)	0	Dysentary
	ආහාර විෂවීම		நெருப்புக்காய்ச்சல் (குடல் காய்ச்சல்)	9	Encephalitis Enteric Fever
9	මානව ජලභීතිකා රෝගය		உணவு நச்சுத் தன்மை		Food poisoning
	ලෙප්ටොස්පයිරෝසියාව		விசர்விலங்குக்கடி நோய்		Human Rabies
	මැලේරියාව		லெப்டோஸ்பைரோசிஸ்		Leptospirosis
	සරම්ප		மலேரியா		Malaria
0	මස්තිෂ්ක පටල පුදාහය	0	சின்னமுத்து		Measles
9	කම්මුල්ගාය		மூளைக்காய்ச்சல் (மெனின்சைடிஸ்)		Meningitis
0	රුබෙල්ලා (ජර්මන් සරම්ප)	•	கூகைக்கட்டு	•	Mumps
9	සංජාතීය රුබෙල්ලා රෝගය		ருபெல்லா/ருபெல்லா நோயுடன் பிறப்பு		Rubella / Congenital Rubella
0	සරල කල්පවත්නා උණ		7 நாட்களுக்கு மேல் தொடரும்	100	Syndrom
0	පිටගැස්ම .		சாதாரண காய்ச்சல் ஏற்புவலி		Simple Continued Fever of over
0	නවජන්ම පිටගැස්ම		ஏந்புவல் பிறந்த முதல் மாதத்தில் ஏற்புவலி		7days or more
0	ටයිපස් උණ		கைபசுக் காய்ச்சல்	0.	Tetanus
0	වෛරස් යාකෘති පුදාහය		வைரசு ஈரல் அழற்சி	•	Neonatal Tetanus
0	කක්කල් කැස්ස		குக்கல்		Typhus Fever
0	ක්ෂය රෝගය		காச நோய்	٠	Viral Hepatitis Whooping Cough
			ACCOUNTS AND PROPERTY.	•	Tuberculosis
	<b>ි</b> ෂ්මනයිසිස්		லேயி'மேனியாசிஸ்		Leishmaniasis
	ලෘදුරු	9	தொழுநோய		Leprosy

කරුණාකර මෙතතින් නවන්න / இங்கே மடிக்கவும் / Please Fold Here

රා. සේ. පි. / அரச சேவை / O. S. S

සෞඛා වෛදා නිලධාරි

சுகாதார வைத்திய அதிகாரி

THE MEDICAL OFFICER OF HEALTH

කරුණාකර මෙතතින් අලවත්ත / இங்கே ඉட்டவும் / Please Paste Here

#### EPID/DS/CRS/2013

# SURVEILLANCE OF CONGENITAL RUBELLA SYNDROME (CRS) - CASE INVESTIGATION FORM EPIDEMIOLOGY UNIT, MINISTRY OF HEALTH

The Medical Officer/Hospital and REE/MOH should carry out the investigation personally. Necessary data should be obtained from the mother of the new baby/BHT/Physician/investigation reports/diagnosis cards. Early investigation and return is essential.

			Serial No:					
A. GENERAL								
Date of notification to MOH     Date of notification to Epide     Name of the reporting Institution	emiology Unit	tal	(dd/mm/vv)			ianya generati in in	CALLEGE STATE	
4. Ward No:		****						
6. Name of the hospital where								
7. Ward No:						************	***	
8. BHT No:								
B. PARTICULARS OF PA	TIENT (Plea	ase (✓ ) appropriate bo	x where appli	cable)				
Name of patient (BLOCK I								
<ol><li>Name of the parent/guardi</li></ol>	an	***************************************						
11. Residential Address:								
12. Date of Birth :		(dd/mm/yy)						
13. Age 14	l. Sex	15. Ethnic group						
	] 1. Male ] 2. Female	1. Sinhalese 2. Tamil	16. Mothers o					
113 World's Days	1211 Omalo	3. Moor 4. Others	1					
		9. Unknown	18. MOH area					
B. PRESENT ILLNESS /O	UTCOME					Salayan (	Preparation of the	
19. Date of detection of signs	and 2	Outcome of the event		AND STREET OF THE PERSON NAMED IN		I S Mile Mulling Lift III		2045
symptoms of CRS:	-	1. Still under treatment		23. If trans	sferred,	name of	hospital	
		2. Died		********				
dd mm yy	_	3. Transferred		24. Was p		ansferred	from sor	ne
20. Where did the patient	-	4. Discharged			nospital			
detect first	22	2. Date of discharge, transfer	or death	Yes L	] / No [	1		
1. Government hospital		(where relevant)	or dodin	25. If "yes"	" where	was the	nationt	
2. Private hospital					rred from		patient	
<ul><li>3. Medical Officer of Health</li><li>4. Private practitioner</li></ul>	n	d d m m y y						
5. Ayurvedic institution								
6. Other (specify)								
. CLINICAL DATA					in de l'étable	cacamatas	SOURCE CONTRACT	
urveillance Case definition:								
hild <1 year of age with mater	nal history of	Rubella infection and/or follo	wing signs and s	ymptoms.				
List A		List B	aboratory data	consistent	For	office u	se only	7014 55
☐ 1. Cateract/s			with Congenital F	Rubella		npatible		
2. Congenital glaucoma		Purpura Splenomegaly	positive resu	It of		e definition	on.	
3. Congenital hearth disea	se 3. N	/licrocephaly	rubella IgM		1763(1)	1. Yes 2. No		
4. Loss of hearing 5. Pigmentary Retinopathy		Mental Retardation	3			2. 140		
_ o. riginentary Retinopathy		Meningo-encephalitis Radiolucent bone disease						
	☐ 7. J	aundice						
	(	within 24hr of delivery)						

	Date of collection of specimen (dd/mm/yy)	Laboratory MRI/ other govt./ private/ not known	Results (mark NA if te results are not availab and PP if pending)
1. maternal IgG persisting >6/52 in infant		The state of the s	and FF is pending)
2. rubella specific lgM			
3. virus isolation / PCR			
MATERNAL HISTORY     Age of mother at time of delivery:	F. MOTHER'S IMMUNIZATIO  34. Was the mother immunized for		CT HISTORY
years  Did the mother have a rubella-like illness during the present pregnancy?  1. yes  2. no  3. not known  If yes, period of gestation at the time of illness  in weeks  not known  Which of the following symptoms and signs were present?  1. fever  2. rash  3. lymphadenopathy  4. conjunctivitis  5. arthritis/arthralgia  6. others (specify)  Was rubella serologically confirmed during pregnancy?	35. If yes, date of vaccination:  d d m m y y  not known  36. Type of vaccine used:  1. Rubella 3. MR  2. MMR 4. Not kno  37. Place of vaccination  1. MOH clinic  2. school  3. government hospital  4. private dispensary/surger  5. private hospital  6. other (specify)  7. not known  38. If not immunized, reason:  1. medical contraindication  2. unaware of the need for v  3. non-availability of vaccine	or suspeindex preindex preinde	s
1. yes 2. no 3. not known	4. no faith in the vaccine 5. others (specify) 6. not known	Time bety development	PR OFFICE USE ween immunization and ent of maternal infection yrs months

# Measles / Rubella Register Format

					*				
								Serial Nui (Annual nui	
								Diseas	se
**************************************								Name of the Patient	
						28		Age DOB	
								Sex	
						100		Ward/ OPD	
								OPD number	PUT/
						1		Date of adn	nission
								Date of onse	et (rash)
						7)		dose	Vaccination MMR/MR/Mea sles/ Rubella
8	*		7	1				2 <sup>nd</sup> dose	nation MR/Mea Is/ ella
							*	Residential address	
2						, a		<b>To MOH</b> (H 544)	Date of notification
							\$	To Epid Unit (EPID/151/1/2013)	e of cation
								Blood for IgM	Spe collec confir (da
								Virus isolation swabs	Specimen collection for confirmation (date & result)

# **CRS** Register Format

								Serial Num (Annual num	
					5			Patient & Name of the mother	Name of the
							XX	detectio n of CRS & DOB	Age
			4					Sex	R .
								Ward/ Unit	
		f						ВНТ	
								Date of adm	ission
						Ā		Date of dete	ection
								Mother's vacci status Rubella	
7	e. 15.	2.0						Residential address	
								<b>To MOH</b> (H 544)	Date of notification
								To Epid Unit (EPID/DS/CRS/2013)	tion
	8		•					Blood for IgM	Specimen collection for confirmation (date & result)
				To a				Virus isolation swabs	collection mation result)

FORM: EPID/37/5/R2004

# WEEKLY REPORTING FORM FOR AFP\*, MEASLES, RUBELLA /CRS CASES FROM HOSPITALS

(SENTINEL SITES)

Disease	Name of the patient	Age .	Sex	Ward	B.H.T. No.	D.O.A	Date of onset	Residential address
				,				
								, a. v
,					·			
opy to R hepid@s	egional Epid litnet.lk by H	lemiolog lead of ti	ist, Tel: he institu	2695112 ution/IC	2, 2681548 N/PHI or	8, Fax: 26 any other	96583, E-n identified	FORM: BPID/37/5/R200
· i	WEEKLY	KEPUI	KIING	FURN	HOSI	PITALS		RUBELLA/CRS CASES FROM
NSTITUT	WEEKLY		.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		HOSI (SENTIN	20.77	s)	RUBELLA/CRS CASES FROM
NSTITUT	ION:		.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		HOSI (SENTIN	PITALS NEL SITES	Date of	
NSTITUT	reporting: (	Saturda	y to Fri	day) 🔲	HOSI (SENTIN	PITALS NEL SITES	Date of	200
NSTITUT	reporting: (	Saturda	y to Fri	day) 🔲	HOSI (SENTIN	PITALS NEL SITES	Date of	200
NSTITUT	reporting: (	Saturda	y to Fri	day) 🔲	HOSI (SENTIN	PITALS NEL SITES	Date of	

EPID/DS/MEASLES/2016

SURVEILLANCE OF MEASLES - CASE INVESTIGATION FORM EPIDEMIOLOGY UNIT MINISTRY OF HEALTH The MOH should do the investigation personally. Necessary data should be obtained from the hospital by reference to the BHT/Physician or from the diagnosis card, Early investigation and return is essential. Week ending Date of ID Register No : Mea / of Notification Confirmation A. PARTICULARS OF PATIENT (Please ( √) appropriate box where applicable) 1. Name of patient (BLOCK LETTERS) ..... 2. Residential Address: ..... Contact Number : ..... email : ..... 3. Date of Birth : \_\_\_/ \_\_\_ / \_\_\_\_\_ (dd/mm/yy) 4. Age 5. Sex 6. Ethnic group 7. Occupation 8. RDHS area 9. MOH area 1. Sinhalese
2. Tamil 1. Male 2. Female y y / mm3. Moor 4. Others 9. Unknown **B. PRESENT ILLNESS /OUTCOME** 10. (a) Date of onset of fever 12. Was patient admitted to hospital? 17. Outcome of the case 1. Yes (If "Yes" question 13) 1. Cured dd mm y y ☐ 2. No (If "No" skip to question 17) 2. Died 3. Complication (b) Date of onset of rash 13. If yes, date of admission: 18. Date of discharge, transfer or death d m m y y m m d d m m У У у у 11. (a) Did the patient seek medical 19. If transferred name of hospital 14. Name of hospital: ..... advice 1. Yes 2. No 2 ...... (b) If "Yes" where did the patient 15. Ward:..... first seek medical advice? 20. Was patient transferred from some ☐ 1. Government hospital other hospital 16. BHT No:.... 2. Private hospital 1. Yes 3. Private practitioner 2. No 4. Ayurvedic institution 21. If "Yes", where was the patient (public/private) transferred from? 5. Other (specify) ...... C. CLINICAL DATA Case definition: fever and maculopapular rash with one of cough, coryza (runny nose) or conjunctivitis

					,		
22. Symptoms and signs	Yes	No		23. Complication	s Yes	No	
1. fever				1, none			
<ol><li>masculopapular rash</li></ol>				2. diarrhoea			
3. cough				3. pneumonia			
4. coryza				4. otitis media		П	
<ol><li>conjunctivitis</li></ol>				5. encephalitis		П	
6. other (Specify)				6. other (specify)			
D. LABORATORY FIN	IDINGS						
24. Was blood taken for m	neasles se	rology (measle	es IgM) ? 1. Ye	es 🗌 2. No 🗍			
(a) If yes: 1. Hosp	ital 🗌 2	. Private Pract	itioner 🔲 3. MO	H 4. Other			
(b)							
Investigation (Serology) e.g. IgM / IgG	The second secon	ollection of n (dd/mm/yy)	Date of sent to laboratory	Laboratory (MRI/govt./private)	Results (mark results are not available)		Date of results

If yes: Sample type			Date of Date of sent Name of the		the I	the Date of result		14 5 "				
			collection		labo				+ve -ve		Result	s Ge
☐ (i) swabs (th☐ (ii) secretion☐ (iii) urine☐ (iv) other☐	nroat/nasal gin n (nasal/oral)	gival)										typ
E. MEASLES	VACCINAT	ION STA	TUS				Destroy				A0-5-5	
26. Was Measle	es Containing	Vaccine giv	ven (MCV) [Mea	asles, MR,	MMR]							
			1.	Yes 🗌	2. No [		3.1	Not known	]			
27. If "yes" (a) Number of doses		1 2 2 >2			>2	a second the second						
	(b) source of	of information	on V	accination	card 🔲		His	tory:				
etails of immur	nization											
ose			munization		f vaccine		Batch	number		Place o	of	
st dose		(dd/mm/yy	()	Measle	Measles, MR, MMR					immunization*		
<sup>nd</sup> dose						-						
Other		***************************************				-		-1				
1011 - 15 / 1			Hospital / Priva									
1. Yes [		No 🗆	nyone with feve 3. Not know		ish within <u>3 w</u>	eeks p	rior to	onset of illr	ness ?			
1. Yes [ (if yes, f	2. N fill row 1 – 3 w ient's househo	No  ith details) old or other		vn 🗌	oned a simila					nt of m	easles	s in
1. Yes [ (if yes, f	2. N fill row 1 – 3 w ient's househo	No  ith details) old or other	Not know  close contacts	vn 🗌	oned a simila	r illness	follov		relopme			
1. Yes [ (if yes, f etails of the pat e <u>patient</u> , and	2. N fill row 1 – 3 w tient's househoutheir immuniza	No  ith details) old or other	3. Not know close contacts (fill Row 4 – 7	who develowith details	oped a simila	r illness	follov	ving the dev	relopme	nt of m	or MC\	ot .
1. Yes [ (if yes, f etails of the pat e patient, and  a. contacts with	2. N fill row 1 – 3 w tient's househoutheir immuniza	No  ith details) old or other	3. Not know close contacts (fill Row 4 – 7	who develowith details	oped a simila	r illness	follow Relati	ving the dev	velopme Vaccii	nated fo	or MC\	ot .
1. Yes [ (if yes, f) etails of the pat e patient, and a. contacts with imilar disease or to onset of	2. Nfill row 1 – 3 with their immunization	No  ith details) old or other	3. Not know close contacts (fill Row 4 – 7	who develowith details	oped a simila	r illness	follow Relati	ving the dev	velopme Vaccii	nated fo	or MC\	ot .
1. Yes [ (if yes, f) etails of the pat e patient, and  a. contacts with imilar disease or to onset of ess in the	2. Name	No  ith details) old or other	3. Not know close contacts (fill Row 4 – 7	who develowith details	oped a simila	r illness	follow Relati	ving the dev	velopme Vaccii	nated fo	or MC\	ot .
1. Yes [ (if yes, f) etails of the pat e patient, and  a. contacts with imilar disease or to onset of ess in the ient c. contacts who	2. N fill row 1 – 3 w tient's househo their immuniza  Name	No  ith details) old or other	3. Not know close contacts (fill Row 4 – 7	who develowith details	oped a simila	r illness	follow Relati	ving the dev	velopme Vaccii	nated fo	or MC\	ot .
1. Yes [ (if yes, f) etails of the pat e patient, and  a. contacts with elimilar disease or to onset of ess in the elient  b. contacts who veloped similar ess after	2. Name  Name	No  ith details) old or other	3. Not know close contacts (fill Row 4 – 7	who develowith details	oped a simila	r illness	follow Relati	ving the dev	velopme Vaccii	nated fo	or MC\	ot .
1. Yes [ (if yes, f) etails of the pate patient, and a. contacts with similar disease or to onset of ess in the tient by cloped similar ess after neact of the	2. N fill row 1 – 3 w itent's househoutheir immunized  Name  1 2 3 4	No  ith details) old or other	3. Not know close contacts (fill Row 4 – 7	who develowith details	oped a simila	r illness	follow Relati	ving the dev	velopme Vaccii	nated fo	or MC\	,
1. Yes [ (if yes, f) etails of the patie patient, and  a. contacts with similar disease or to onset of ess in the tient by coloped similar ess after neact of the	2. Name  Name  1 2 3 4 5	No  ith details) old or other	3. Not know close contacts (fill Row 4 – 7	who develowith details	oped a simila	r illness	follow Relati	ving the dev	velopme Vaccii	nated fo	or MC\	ot .
1. Yes [ (if yes, f) etails of the patie patient, and a. contacts with similar disease or to onset of ess in the tient b. contacts who veloped similar ess after ntact of the ex patient	2. Name  Name  Name  1  2  3  4  5  6  7	No ☐ ith details) old or other ation status	3. Not know close contacts (fill Row 4 – 7	who devel with details	oped a simila s)  Date of one rash	r illness	follow Relati	ving the dev	velopme Vaccii	nated fo	or MC\	ot
1. Yes [ (if yes, f) etails of the patient, and le patient	2. Name  Name  Name  1  2  3  4  5  6  7	No ☐ ith details) old or other ation status	3. Not know close contacts (fill Row 4 – 7	who devel with details	oped a simila s)  Date of one rash	r illness	follow Relati	ving the devi	velopme Vaccii	nated fo	or MC\	ot
1. Yes [ (if yes, f) etails of the patie patient, and a. contacts with similar disease or to onset of ess in the tient b. contacts who veloped similar ess after ntact of the ex patient	2. Name  Name  Name  1  2  3  4  5  7  naving a histor	No  ith details)  old or other ation status	3. Not know close contacts (fill Row 4 – 7  Age	who devel with details  Sex  s prior to il	oped a simila s)  Date of one rash  Iness onset)	r illness	Relati patier	ving the devi	Vaccin Yes	nated fo	or MC\	ot .
1. Yes [ (if yes, f) etails of the pate patient, and a. contacts with similar disease or to onset of ess in the cient on contacts who reloped similar ess after stact of the ex patient.  Is the patient hes: (i) Countally	2. N fill row 1 – 3 w lient's househo their immuniza  Name  1 2 3 4 5 6 7 naving a histor ry of travel :	No  ith details)  old or other ation status	3. Not know close contacts (fill Row 4 – 7  Age	who devel with details  Sex  s prior to il	oped a simila s)  Date of one rash  Iness onset)	r illness	Relati patier	ving the devi	Vaccin Yes	nated fo	or MC\	ot .
1. Yes [ (if yes, f) etails of the pate e patient, and a. contacts with similar disease or to onset of ess in the tient oveloped similar ess after ntact of the ex patient  Is the patient hes: (i) Countal	2. Name  Name  Name  1  2  3  4  5  7  naving a histor	No  ith details)  old or other ation status	3. Not know close contacts (fill Row 4 – 7  Age	who devel with details  Sex  s prior to il	oped a simila s)  Date of one rash  Iness onset)	r illness	Relati patier	ving the devi	Vaccin Yes	nated fo	or MC\	ot .
1. Yes [ (if yes, f) etails of the pate patient, and  a. contacts with similar disease or to onset of ess in the tient  b. contacts who veloped similar ess after lact of the ex patient  Is the patient fies: (i) Country (ii) History	2. N fill row 1 – 3 w lient's househo their immuniza  Name  1 2 3 4 5 6 7 naving a histor ry of travel :	No  ith details)  old or other ation status	3. Not know close contacts (fill Row 4 – 7  Age	who devel with details  Sex  s prior to il	oped a simila s)  Date of one rash  Iness onset)	r illness	Relati patier	ving the devi	Vaccin Yes	nated fo	or MC\	ot .
1. Yes [ (if yes, f) etails of the patie patient, and a. contacts with similar disease or to onset of ess in the tient b. contacts who veloped similar ess after stact of the ex patient  Is the patient fies: (i) Country (ii) History marks	2. Name Name Name 1 2 3 4 5 6 7 naving a historry of travel :	No  ith details)  pld or other ation status  ry of travel attornation at the contact in a	3. Not know close contacts (fill Row 4 – 7	who devel with details  Sex  s prior to il	oped a similars)  Date of one rash  Iness onset)	set of	Relati patier	ionship to	Vaccii Yes	nated for No	or MCV	ot
1. Yes [ (if yes, f) etails of the pate patient, and a. contacts with similar disease or to onset of ess in the tient b. contacts who veloped similar ess after stact of the ex patient  Is the patient f es: (i) Country (ii) History	2. Name Name Name 1 2 3 4 5 6 7 naving a historry of travel :	No  ith details)  pld or other ation status  ry of travel attachment in a	3. Not know close contacts (fill Row 4 – 7	who devel with details  Sex  s prior to il	oped a similars)  Date of one rash  Iness onset)	set of	Relati patier	ionship to	Vaccin Yes	nated for No	or MCV	ot nown
1. Yes [ (if yes, f) etails of the pate patient, and  a. contacts with similar disease or to onset of ess in the tient of the expatient of the expatient of the expatient of the expatient (ii) History marks	2. N fill row 1 – 3 w itent's househotheir immunization Name  Name  1 2 3 4 5 6 7  naving a histor ry of travel: y of Measles of	No  ith details)  old or other ation status  ry of travel a	3. Not know close contacts (fill Row 4 – 7  Age  abroad (3 week	who devel with details  Sex  s prior to il	oped a similars)  Date of one rash  Iness onset)	set of	Relati patier	ionship to nt	Vaccii Yes	nated for No	or MCV	ot nown
1. Yes [ (if yes, f) etails of the pate patient, and a. contacts with similar disease or to onset of ess in the tient oveloped similar ess after expatient  Is the patient fies: (i) Country (ii) History marks	2. Name Name  Name  1 2 3 4 5 6 7	No	3. Not know close contacts (fill Row 4 – 7	who devel with details  Sex  s prior to il	oped a simila s)  Date of one rash  Iness onset)	set of	Relati patier	ionship to nt  FOR	Vaccii Yes  No  R OFFIC	nated for No	E ONL	ot nown
1. Yes [ (if yes, f) (if yes,	2. N fill row 1 – 3 w itent's househotheir immunization Name  Name  1 2 3 4 5 6 7  naving a histor ry of travel: y of Measles of	No	3. Not know close contacts (fill Row 4 – 7  Age  abroad (3 week	who devel with details  Sex  s prior to il	oped a simila s)  Date of one rash  Iness onset)	set of	Relati patier	ionship to nt	Vaccii Yes  No  R OFFIC Labor Epide	CE US	E ONL	ot nown
1. Yes [ (if yes, f) (if yes,	2. Name Name  Name  1 2 3 4 5 6 7	No	3. Not know close contacts (fill Row 4 – 7	who devel with details  Sex  s prior to il	oped a simila s)  Date of one rash  Iness onset)	set of	Relati patier	ionship to nt  FOR Final C	Vaccii Yes  No  R OFFIC Labor Epide confin	CE US	E ONL	ot nown

EPID/DS/RUBELLA/2007

\_\_\_ 2. No

# SURVEILLANCE OF RUBELLA - CASE INVESTIGATION FORM

EPIDEMIOLOGY UNIT, MINISTRY OF HEALTH

The MOH should do the investigation personally. Necessary data should be obtained from the hospital by reference to the BHT / Physician or from the diagnosis card. Early investigation and return are essential. Week ending Please write the Serial No given in the Infectious Serial no: of notification Disease Register (ID Register) in the MOH office A. PARTICULARS OF PATIENT (Please tick ( ) the appropriate box where applicable) Name of patient (BLOCK LETTERS) ...... 2. Residential address: .. 3. Date of birth: (dd/mm/yyyy) 4. Age 5. Sex 6. Ethnic group 8. DPDHS division (district) 7. Occupation 9. MOH area 1. male 1. Sinhalese 2. female 2. Tamil y y/m m 3. not known 3. Moor FOR OFFICE USE ONLY 4. others ☐5. not known **B. PRESENT ILLNESS/OUTCOME** 10. Date of onset of symptoms: 12. Was patient admitted to hospital? 17. Date of discharge/transfer or death: 1. ves > to Q. 13 d m m skip 18. If transferred, name of hospital to Q. 21 11. Where did the patient first seek 3. not known medical advice? 13. If yes, date of admission: 19. Was patient transferred from some other 1. government hospital hospital? 2. private hospital 1. yes 2. no 3. private practitioner 14. Name of hospital: 20. If "yes", where was the patient transferred from? 4. Ayurvedic institution (public/private) 21. Outcome of the case 15. Ward: ..... 5. other (specify) 1. cured 3. transferred 16. BHT no: ..... ..... 2. died 4. not known C. CLINICAL DATA Case definition: An illness with generalized macular papular rash, fever and arthralgia/arthritis, lymphadenopathy or conjunctivitis 22. Symptoms and signs 23. Complications 1. fever 1. encephalitis 2. rash 2. other (specify): ..... 3. lymphadenopathy For office use only 4. conjunctivitis Compatible with the 5. arthritis/arthralgia case definition: 6. other (specify): ..... ... 1. Yes

Inv							
Investigation		Date of collection of specimen (dd/mm/yy)	Labora (MRI/ other go not kno	vt./ private/	Results (mark NA if test results are no available and PP if pending)		
	1 <sup>st</sup> specimen						
2. lgG :	2 <sup>nd</sup> specimen						
3. IgM							
4. Virus	isolation						
26. Was	rubella/MMR/ yes	Section 2		ess?			
	Dose	(dd/mm/yy)	Type of vaccine**	Batch number	Place of immunization***		
	1 <sup>st</sup> dose			The Late			
	2 <sup>nd</sup> dose						
	Other	s not known but the particular dos					
9. Was th ☐ 1. y . EXPO	DSURE DUR ne patient preg period of gest	intact with a suspected / known 3. not known  ING PREGNANCY (for feet an ant at the time of illness?  ation in weeks:	emales of reproduct 1. yes 2. no 2	tive age only)  3. not known			
	net mathana u	the head on a code add ! !-		the hahy is found			
l pregna RS case	investigation	/ho had an acute attack sho form No EPID/DS/CRS/2007	uld be followed up. If 7 must be filled.	are saby is louriu	to have acquired CRS, a separate		
l pregna RS case	investigation	/ho had an acute attack sho	7 must be filled.				
nportan II pregna RS case 2. Remar	ks:	TOTH NO EPID/DS/CRS/200	7 must be filled.				

# Specimen Request Form: Measles & Rubella National Reference Laboratory Medical Research Institute, Colombo

9	Name of the Patient			
0	Age :		Sex :	
0	Hospital	:		
9	Ward	:		
•	BHT No:			
9	Address of patient's residence	:		
9	District of patient's residence	:		
9	Date of onset of fever		DO MM AAAA	
9	Date of onset of rash	:	DD MM YYYY	
•	Specimen collection	:	Blood	Throat swab
			Date of collection	Date of collection
			DD MW YYYY	DD WW AAAA
			(3 ml blood preferably serum separated & transport in cold box)	(throat swabs in virus transport media in Ice)
•	Date of dispatch to MRI	:	OD MM YYFY	2
*Ple EPI	ase notify the case to <u>Medical</u> D/151/1/2013 – Blue Form)	of	ficer of health (H 544)	& to <u>Epidemiology Unit</u>
			Signature of M	edical Officer
	LA	BO	DRATORY USE	
	Date received of sample	:	Serology	Virus Isolation
			DD WW AAAA	DD MM YYYY
	Sample accepted	:	Yes / No	Yes / No

(Received within 72 hrs after collection, sent in cold chain, satisfactory sample)